← Leaderboards
Mark N Shahan
Quintessence Biosciences, Inc.
$917,452
Attributed
$917,452
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $634.1K · FY2007–09$1M$750K$500K$250K$0
'07
'08
'09
Funding mix
By agency
NIH$917,452 · 3
By mechanism
R44$634,106 · 1
R43$283,346 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsProductionInhibitor/AntagonistIn VivoPancreatic RibonucleasePhysiciansDoseFamily SuidaeInterestIn VitroComplexPancreasAmino Acid SubstitutionPharmaceutical PreparationsBinding (Molecular Function)Commercial ApplicationEnzymesExhibitsCancer CellCancer PatientCancer TherapyCancer TypeAdverse EffectsProgram Development